YJYaqi Jia

Yaqi Jia

*This is an algorithmically generated author record based on publicly available information.

Yaqi Jia has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of Celiac Disease in China Among High‐Risk Populations: A Systematic Review and Meta‐Analysis

    by Ying Lian Xiao, Ya Qi Jia, Li Qun Gu, Min Hu Chen

    Objective: We conducted this systematic review and meta‐analysis to summarize the prevalence of celiac disease (CeD) among high‐risk populations in China. Methods: A systematic search was conducted in PubMed, EMBASE, Cochrane Library, Web of Science, and four Chinese databases to identify studies published up to December 10, 2024 on the prevalence of CeD in different regions of China. The high‐risk populations included patients with irritable bowel syndrome, gastrointestinal symptoms, autoimmune disease, low body mass index, short stature, etc. Data were extracted from the included studies by two reviewers independently using a standardized data extraction form. Regional prevalence estimates were weighted using China Population Census Yearbook 2020 data. The pooled prevalence of CeD was summarized using random‐effects models. Results: Twenty‐eight studies involving 9531 individuals were included. Biopsy‐confirmed prevalence and seroprevalence varied widely by region. Central China had the highest biopsy‐confirmed prevalence of CeD in high‐risk populations (4.55%, 95% confidence interval [CI] 0.66%–8.44%), followed by North China (3.60%, 95% CI 1.75%–6.08%) and East China (2.50%, 95% CI 1.39%–3.94%). Northeast China led in seroprevalence (7.10%, 95% CI 1.14%–13.05%), followed by Central China (4.42%, 95% CI 1.04%–9.98%), East China (4.37%, 95% CI 2.12%–7.38%), and North China (4.35%, 95% CI 2.39%–6.86%). The biopsy‐confirmed prevalence and seroprevalence of CeD among high‐risk populations in China were 3.69% and 4.43%, respectively. Conclusion: CeD prevalence appears to be significant among high‐risk populations and varies by geographical regions in China.

  • Angiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury

    by Sherry G. Mansour, Pavan K. Bhatraju, Steven G. Coca, Wassim Obeid, Francis P. Wilson, Ian B. Stanaway, Yaqi Jia, Heather Thiessen-Philbrook, Alan S. Go, T. Alp Ikizler, et al.

    Background: The mechanisms underlying long-term sequelae after AKI remain unclear. Vessel instability, an early response to endothelial injury, may reflect a shared mechanism and early trigger for CKD and heart failure. Methods: To investigate whether plasma angiopoietins, markers of vessel homeostasis, are associated with CKD progression and heart failure admissions after hospitalization in patients with and without AKI, we conducted a prospective cohort study to analyze the balance between angiopoietin-1 (Angpt-1), which maintains vessel stability, and angiopoietin-2 (Angpt-2), which increases vessel destabilization. Three months after discharge, we evaluated the associations between angiopoietins and development of the primary outcomes of CKD progression and heart failure and the secondary outcome of all-cause mortality 3 months after discharge or later. Results: Median age for the 1503 participants was 65.8 years; 746 (50%) had AKI. Compared with the lowest quartile, the highest quartile of the Angpt-1:Angpt-2 ratio was associated with 72% lower risk of CKD progression (adjusted hazard ratio [aHR], 0.28; 95% confidence interval [CI], 0.15 to 0.51), 94% lower risk of heart failure (aHR, 0.06; 95% CI, 0.02 to 0.15), and 82% lower risk of mortality (aHR, 0.18; 95% CI, 0.09 to 0.35) for those with AKI. Among those without AKI, the highest quartile of Angpt-1:Angpt-2 ratio was associated with 71% lower risk of heart failure (aHR, 0.29; 95% CI, 0.12 to 0.69) and 68% less mortality (aHR, 0.32; 95% CI, 0.15 to 0.68). There were no associations with CKD progression. Conclusions: A higher Angpt-1:Angpt-2 ratio was strongly associated with less CKD progression, heart failure, and mortality in the setting of AKI.


  • Open Access

    Trends in the procurement and discard of kidneys from deceased donors with acute kidney injury

    by Caroline Liu, Sami Alasfar, Peter P. Reese, Sumit Mohan, Mona D. Doshi, Isaac E. Hall, Heather Thiessen Philbrook, Yaqi Jia, Darren Stewart, Chirag R. Parikh


  • Open Access

    Urinary EGF and MCP-1 and risk of CKD after cardiac surgery

    by Steven Menez, Wenjun Ju, Rajasree Menon, Dennis G. Moledina, Heather Thiessen Philbrook, Eric McArthur, Yaqi Jia, Wassim Obeid, Sherry G. Mansour, Jay L. Koyner, et al.

    BACKGROUND: Assessment of chronic kidney disease (CKD) risk after acute kidney injury (AKI) is based on limited markers primarily reflecting glomerular function. We evaluated markers of cell integrity (EGF) and inflammation (monocyte chemoattractant protein-1, MCP-1) for predicting long-term kidney outcomes after cardiac surgery. METHODS: We measured EGF and MCP-1 in postoperative urine samples from 865 adults who underwent cardiac surgery at 2 sites in Canada and the United States and assessed EGF and MCP-1’s associations with the composite outcome of CKD incidence or progression. We used single-cell RNA-Seq (scRNA-Seq) of AKI patient biopsies to perform transcriptomic analysis of programs corregulated with the associated genes. RESULTS: Over a median (IQR) follow-up of 5.8 (4.2–7.1) years, 266 (30.8%) patients developed the composite CKD outcome. Postoperatively, higher levels of urinary EGF were protective and higher levels of MCP-1 were associated with the composite CKD outcome (adjusted HR 0.83, 95% CI 0.73–0.95 and 1.10, 95% CI 1.00–1.21, respectively). Intrarenal scRNA-Seq transcriptomes in patients with AKI-defined cell populations revealed concordant changes in EGF and MCP-1 levels and underlying molecular processes associated with loss of EGF expression and gain of CCL2 (encoding MCP-1) expression. CONCLUSION: Urinary EGF and MCP-1 were each independently associated with CKD after cardiac surgery. These markers may serve as noninvasive indicators of tubular damage, supported by tissue transcriptomes, and provide an opportunity for novel interventions in cardiac surgery. TRIAL REGISTRATION: ClinicalTrials.gov NCT00774137. FUNDING: The NIH funded the TRIBE-AKI Consortium and Kidney Precision Medicine Project. Yale O’Brien Kidney Center, American Heart Association, Patterson Trust Fund, Dr. Adam Linton Chair in Kidney Health Analytics, Canadian Institutes of Health Research, ICES, Ontario Ministry of Health and Long-Term Care, Academic Medical Organization of Southwestern Ontario, Schulich School of Medicine & Dentistry, Western University, Lawson Health Research Institute, Chan Zuckerberg Initiative Human Cell Atlas Kidney Seed Network.